Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics
- PMID: 36984782
- PMCID: PMC10056171
- DOI: 10.3390/metabo13030342
Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics
Abstract
A number of studies have assessed the impact of SARS-CoV-2 infection and COVID-19 severity on the metabolome of exhaled air, saliva, plasma, and urine to identify diagnostic and prognostic biomarkers. In spite of the richness of the literature, there is no consensus about the utility of metabolomic analyses for the management of COVID-19, calling for a critical assessment of the literature. We identified mass spectrometric metabolomic studies on specimens from SARS-CoV2-infected patients and subjected them to a cross-study comparison. We compared the clinical design, technical aspects, and statistical analyses of published studies with the purpose to identify the most relevant biomarkers. Several among the metabolites that are under- or overrepresented in the plasma from patients with COVID-19 may directly contribute to excessive inflammatory reactions and deficient immune control of SARS-CoV2, hence unraveling important mechanistic connections between whole-body metabolism and the course of the disease. Altogether, it appears that mass spectrometric approaches have a high potential for biomarker discovery, especially if they are subjected to methodological standardization.
Keywords: COVID-19; biomarkers; diagnosis; mass-spectrometry; metabolomics; prognostic.
Conflict of interest statement
MB and SD declare no conflict of interest. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’s wife, Laurence Zitvogel has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.
Figures


Similar articles
-
Saliva metabolomic profile of COVID-19 patients associates with disease severity.Metabolomics. 2022 Oct 22;18(11):81. doi: 10.1007/s11306-022-01936-1. Metabolomics. 2022. PMID: 36271948 Free PMC article.
-
Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19.Sci Rep. 2022 Jun 15;12(1):9959. doi: 10.1038/s41598-022-14292-w. Sci Rep. 2022. PMID: 35705608 Free PMC article.
-
Untargeted detection of the carbonyl metabolome by chemical derivatization and liquid chromatography-tandem mass spectrometry in precursor ion scan mode: Elucidation of COVID-19 severity biomarkers.Anal Chim Acta. 2022 Mar 1;1196:339405. doi: 10.1016/j.aca.2021.339405. Epub 2022 Jan 4. Anal Chim Acta. 2022. PMID: 35151400
-
Mass spectrometric based approaches in urine metabolomics and biomarker discovery.Mass Spectrom Rev. 2017 Mar;36(2):115-134. doi: 10.1002/mas.21455. Epub 2015 Apr 16. Mass Spectrom Rev. 2017. PMID: 25881008 Review.
-
Amino Acid Metabolism in Leukocytes Showing In Vitro IgG Memory from SARS-CoV2-Infected Patients.Diseases. 2024 Feb 23;12(3):43. doi: 10.3390/diseases12030043. Diseases. 2024. PMID: 38534967 Free PMC article. Review.
Cited by
-
Early Metabolomic and Immunologic Biomarkers as Prognostic Indicators for COVID-19.Metabolites. 2024 Jul 9;14(7):380. doi: 10.3390/metabo14070380. Metabolites. 2024. PMID: 39057703 Free PMC article.
-
Systemic perturbations in amino acids/amino acid derivatives and tryptophan pathway metabolites associated with murine influenza A virus infection.Virol J. 2023 Nov 21;20(1):270. doi: 10.1186/s12985-023-02239-0. Virol J. 2023. PMID: 37990229 Free PMC article.
-
COVIDomics: Metabolomic Views on COVID-19.Metabolites. 2024 Dec 12;14(12):702. doi: 10.3390/metabo14120702. Metabolites. 2024. PMID: 39728483 Free PMC article.
-
Comprehensive clinical and metabolomics profiling of COVID-19 Mexican patients across three epidemiological waves.Front Mol Biosci. 2025 Jun 18;12:1607583. doi: 10.3389/fmolb.2025.1607583. eCollection 2025. Front Mol Biosci. 2025. PMID: 40607062 Free PMC article.
-
Lipidome is a valuable tool for the severity prediction of coronavirus disease 2019.Front Immunol. 2024 May 10;15:1337208. doi: 10.3389/fimmu.2024.1337208. eCollection 2024. Front Immunol. 2024. PMID: 38799463 Free PMC article.
References
-
- World Health Organization . WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. World Health Organization; Geneva, Switzerland: 2021. pp. 1–5.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous